Purdue Pharma and its owners, the Sackler family, are offering to settle more than 2,000 lawsuits against the company for $10B to $12B, according to 2 people familiar with the mediation.
starting and sustaining the opioid crisis.
In a statement to NBC News, the company said:"While Purdue Pharma is prepared to defend itself vigorously in the opioid litigation, the company has made clear that it sees little good coming from years of wasteful litigation and appeals." The in-kind drugs, combined with profits from the sale of drugs, would add up to a total Purdue settlement ranging from $7 billion to $8 billion, according to two people familiar with the offer.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Purdue Pharma offers $10-12 billion to settle opioid claimsPurdue Pharma and its owners, the Sackler family, are offering to settle more than 2,000 lawsuits against the company for $10B to $12B, according to 2 people familiar with the mediation.
Read more »
Report: Purdue Pharma Offered $10-12 Billion To Settle Thousands Of Opioid LawsuitsThe Sackler family is facing increasing blame for fueling the opioid crisis.
Read more »
Purdue Pharma in discussion on $10 billion-$12 billion offer to settle opioid claims: sourcesOxyContin maker Purdue Pharma and its owners, the Sackler family, is in discussi...
Read more »
Big pharma in court—the Johnson & Johnson rulingOn this week’s “Money talks” podcast: the ruling against Johnson & Johnson in Oklahoma, Jim Bullard of stlouisfed talks monetary policy and can humour strengthen a bottom line?
Read more »
It Is Too Early for Pharma Investors to Cheer Opioid VerdictHold the celebration: The opioid litigation cloud hanging over drug stocks won’t clear up soon, despite an Oklahoma judge’s ruling that Johnson & Johnson is liable for fueling the opioid crisis.
Read more »
Shares of pharma companies soar after Johnson & Johnson sees smaller-than-expected opioid fineShares of major pharmaceutical companies surged in after-hours trading Monday following a smaller-than-expected fine for Johnson & Johnson.
Read more »